Literature DB >> 12543289

Tachycardia-induced cardiomyopathy.

Ernesto Umana1, C Arturo Solares, Martin A Alpert.   

Abstract

Systolic dysfunction associated with chronic tachyarrhythmias, known as tachycardia-induced cardiomyopathy, is a reversible form of heart failure characterized by left ventricular dilatation that is usually reversible once the tachyarrhythmia is controlled. Its development is related to both atrial and ventricular arrhythmias. The diagnosis is usually made following observation of a marked improvement in systolic function after normalization of heart rate. Clinicians should be aware that patients with unexplained systolic dysfunction may have tachycardia-induced cardiomyopathy, and that controlling the arrhythmia may result in improvement and even complete normalization of systolic function.

Entities:  

Mesh:

Year:  2003        PMID: 12543289     DOI: 10.1016/s0002-9343(02)01472-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  51 in total

1.  Stress-related cardiomyopathies.

Authors:  Christian Richard
Journal:  Ann Intensive Care       Date:  2011-09-20       Impact factor: 6.925

2.  Resolution of tachycardia-induced cardiomyopathy following ablation of verapamil-sensitive idiopathic left ventricular tachycardia.

Authors:  A Arya; M Haghjoo; P Davari; M A Sadr-Ameli
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

Review 3.  Rate control in the medical management of atrial fibrillation.

Authors:  A J Camm; I Savelieva; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

Review 4.  Perspectives of I(f) inhibition by ivabradine in cardiology.

Authors:  Michael Böhm; Jan-Christian Reil
Journal:  Drugs       Date:  2007       Impact factor: 9.546

5.  Reversal of cardiomyopathy in patients with congestive heart failure secondary to tachycardia.

Authors:  Zhao Donghua; Peng Jian; Xiao Zhongbo; Zhang Feifei; Peng Xinhui; Yang Hao; Liu Fuqiang; Li Yan; Xie Yong; Huang Xinfu; Meng Surong; Wu Muli; Xu Dingli
Journal:  J Interv Card Electrophysiol       Date:  2012-10-23       Impact factor: 1.900

6.  Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine.

Authors:  Pavel Hála; Mikuláš Mlček; Petr Ošťádal; David Janák; Michaela Popková; Tomáš Bouček; Stanislav Lacko; Jaroslav Kudlička; Petr Neužil; Otomar Kittnar
Journal:  J Vis Exp       Date:  2018-02-17       Impact factor: 1.355

Review 7.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Atrial fibrillation: how to approach rate control.

Authors:  Lynda E Rosenfeld
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

Review 9.  50-Year-Old Man With Dyspnea on Exertion, Orthopnea, and Weight Gain.

Authors:  Sae K Jang; Megha Prasad; LaPrincess C Brewer
Journal:  Mayo Clin Proc       Date:  2019-08       Impact factor: 7.616

10.  Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies.

Authors:  J Malcom; O Arnold; Jonathan G Howlett; Anique Ducharme; Justin A Ezekowitz; Martin J Gardner; Nadia Giannetti; Haissam Haddad; George A Heckman; Debra Isaac; Philip Jong; Peter Liu; Elizabeth Mann; Robert S McKelvie; Gordon W Moe; Anna M Svendsen; Ross T Tsuyuki; Kelly O'Halloran; Heather J Ross; Errol J Sequeira; Michel White
Journal:  Can J Cardiol       Date:  2008-01       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.